Austin Journal of Cardiovascular Disease and Atherosclerosis is a peer reviewed academic journal exclusively dedicated to publish diseases that effects cardiovascular system and blood vessels.
The aim of the journal is to provide a forum for cardiologists, cardiac surgeons, general physicians, pharmacologists, internists, researchers, physicians and other health professionals to find most recent advances in the areas of cardiology and cardiovascular diseases.
This open access journal cover all the aspects of cardiovascular disease and stroke such as heart failure, coronary artery disease, congenital heart defects, ischemic heart disease, congenital heart disease, coronary artery disease, electrophysiology, cardiac surgery, cardiomyopathy, valvular heart disease, vascular disease, hypertension and more.
Austin Journal of Cardiovascular Disease and Atherosclerosis is a peer reviewed academic journal exclusively dedicated to publish diseases that effects cardiovascular system and blood vessels.
The aim of the journal is to provide a forum for cardiologists, cardiac surgeons, general physicians, pharmacologists, internists, researchers, physicians and other health professionals to find most recent advances in the areas of cardiology and cardiovascular diseases.
This open access journal cover all the aspects of cardiovascular disease and stroke such as heart failure, coronary artery disease, congenital heart defects, ischemic heart disease, congenital heart disease, coronary artery disease, electrophysiology, cardiac surgery, cardiomyopathy, valvular heart disease, vascular disease, hypertension and more.
Prof. DR. Dr. Rochmad Romdoni, SpJP(K), FINASIM, FIHA, FAsCC. 3rd Pekanbaru Cardiology Update, August 24th 2013. Pangeran Hotel Pekanbaru. Learn more at PerkiPekanbaru.com
Represents 30% of all deaths worldwide (15 million deaths/year)
Leading cause of death and disability
CVD burden in developing countries
Risk factors worldwide
Electrocardiography fundamentals, common cardiovascular diseases, use of ECG in the detection of MI, abnormal bllod electrolyte levels, abnormal rhythms of the heart, tachcardia and bradycardia, prevention of heart diseases, the relevance of sports and exercise, CVD among women and prevention
http://www.thinkred.co.za/get-involved/events | Thousands of people around the globe are affected by at least one type of Cardiovascular Disease (CVD) every day. This only emphasises the importance of heart health in this day and age. Learn what CVD is about the impact that it has had on people over the years. With simple diet and lifestyle changes many diagnosed individuals can overcome this threat.
Pathanatomy main diseases of blood vessels part - 3NEHAADIWAN
Arterial hypertension is one of the major disorder of blood vessels. Hypertension (HTN or HT), also known as high blood pressure (HBP), is a long-term medical condition in which the blood pressure in the arteries is persistently elevated.
Cardiovascular prevention. com is a website for prevention of cardiovascular disease. In this slide presentation you can find the burden of cardiovascular disease in same Countries
Prof. DR. Dr. Rochmad Romdoni, SpJP(K), FINASIM, FIHA, FAsCC. 3rd Pekanbaru Cardiology Update, August 24th 2013. Pangeran Hotel Pekanbaru. Learn more at PerkiPekanbaru.com
Represents 30% of all deaths worldwide (15 million deaths/year)
Leading cause of death and disability
CVD burden in developing countries
Risk factors worldwide
Electrocardiography fundamentals, common cardiovascular diseases, use of ECG in the detection of MI, abnormal bllod electrolyte levels, abnormal rhythms of the heart, tachcardia and bradycardia, prevention of heart diseases, the relevance of sports and exercise, CVD among women and prevention
http://www.thinkred.co.za/get-involved/events | Thousands of people around the globe are affected by at least one type of Cardiovascular Disease (CVD) every day. This only emphasises the importance of heart health in this day and age. Learn what CVD is about the impact that it has had on people over the years. With simple diet and lifestyle changes many diagnosed individuals can overcome this threat.
Pathanatomy main diseases of blood vessels part - 3NEHAADIWAN
Arterial hypertension is one of the major disorder of blood vessels. Hypertension (HTN or HT), also known as high blood pressure (HBP), is a long-term medical condition in which the blood pressure in the arteries is persistently elevated.
Cardiovascular prevention. com is a website for prevention of cardiovascular disease. In this slide presentation you can find the burden of cardiovascular disease in same Countries
Epidemiology of Chronic Non- communicable diseases and ConditionsSheetal Singh
This presentation focuses on the most prevailing Non- Communicable diseases of the world. It includes the problem, causes, risk factors, prevention and worldwide statistics of each disease.
Etiopathogenesis and pharmacotherapy of myocardial infraction
a. the pathophysiology of selected disease states and the rationale for drug therapy;
b. the therapeutic approach to management of these diseases;
c. the controversies in drug therapy;
d. the importance of preparation of individualised therapeutic plans based on diagnosis;
e. needs to identify the patient-specific parameters relevant in initiating drug therapy,
and monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects);
f. describe the pathophysiology of selected disease states and explain the rationale for
drug therapy;
g. summarise the therapeutic approach to management of these diseases including
reference to the latest available evidence;
h. discuss the controversies in drug therapy;
i. discuss the preparation of individualised therapeutic plans based on diagnosis; and
j. identify the patient-specific parameters relevant in initiating drug therapy, and
monitoring therapy (including alternatives, time-course of clinical and laboratory indices of therapeutic response and adverse effects).
Etiopathogenesis and pharmacotherapy of CONGESTIVE CARDIAC FAILURE
a. the pathophysiology of selected disease states and the rationale for drug therapy;
b. the therapeutic approach to management of these diseases;
c. the controversies in drug therapy;
d. the importance of preparation of individualised therapeutic plans based on diagnosis;
e. needs to identify the patient-specific parameters relevant in initiating drug therapy,
and monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects);
f. describe the pathophysiology of selected disease states and explain the rationale for
drug therapy;
g. summarise the therapeutic approach to management of these diseases including
reference to the latest available evidence;
h. discuss the controversies in drug therapy;
i. discuss the preparation of individualised therapeutic plans based on diagnosis; and
j. identify the patient-specific parameters relevant in initiating drug therapy, and
monitoring therapy (including alternatives, time-course of clinical and laboratory indices of therapeutic response and adverse effects).
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
3. • Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood
vessels and they include:
•coronary heart disease – disease of the blood vessels supplying the heart muscle;
•cerebrovascular disease – disease of the blood vessels supplying the brain;
•peripheral arterial disease – disease of blood vessels supplying the arms and legs;
•rheumatic heart disease – damage to the heart muscle and heart valves from
rheumatic fever, caused by streptococcal bacteria;
•congenital heart disease – malformations of heart structure existing at birth;
•deep vein thrombosis and pulmonary embolism – blood clots in the leg veins,
which can dislodge and move to the heart and lungs.
4. Heart attacks and strokes are usually acute events and are mainly caused by a
blockage that prevents blood from flowing to the heart or brain.
The most common reason for this is a build-up of fatty deposits on the inner walls of
the blood vessels that supply the heart or brain.
Strokes can also be caused by bleeding from a blood vessel in the brain or from blood
clots.
The cause of heart attacks and strokes are usually the presence of a combination of
risk factors, such as tobacco use, unhealthy diet and obesity, physical inactivity and
harmful use of alcohol, hypertension, diabetes and hyperlipidaemia.
5. Risk factors for cardiovascular disease
• The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The
effects of behavioural risk factors may show up in individuals as raised blood
pressure, raised blood glucose, raised blood lipids, and overweight and
obesity. These “intermediate risks factors” can be measured in primary care
facilities and indicate an increased risk of developing a heart attack, stroke,
heart failure and other complication
6. • Cessation of tobacco use, reduction of salt in the diet, consuming fruits and
vegetables, regular physical activity and avoiding harmful use of alcohol have
been shown to reduce the risk of cardiovascular disease. In addition, drug
treatment of diabetes, hypertension and high blood lipids may be necessary to
reduce cardiovascular risk and prevent heart attacks and strokes. Health
policies that create conducive environments for making healthy choices
affordable and available are essential for motivating people to adopt and
sustain healthy behaviour.
7. • There are also a number of underlying determinants of CVDs or "the causes of
the causes". These are a reflection of the major forces driving social,
economic and cultural change – globalization, urbanization and population
ageing. Other determinants of CVDs include poverty, stress and hereditary
factors.
8. Epidimology
• CVDs are the number 1 cause of death globally: more people die annually
from CVDs than from any other cause.
• An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Of these deaths,
85% are due to heart attack and stroke.
• Over three quarters of CVD deaths take place in low- and middle-income countries.
• Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2015, 82% are
in low- and middle-income countries, and 37% are caused by CVDs.
• Most cardiovascular diseases can be prevented by addressing behavioural risk factors such as tobacco use,
unhealthy diet and obesity, physical inactivity and harmful use of alcohol using population-wide strategies.
• People with cardiovascular disease or who are at high cardiovascular risk (due to the presence of one or more
risk factors such as hypertension, diabetes, hyperlipidaemia or already established disease) need early detection
and management using counselling and medicines, as appropriate.
9. Why are cardiovascular diseases a development issue in low- and middle-
income countries
• At least three quarters of the world's deaths from CVDs occur in low- and middle-income
countries.
• People in low- and middle-income countries often do not have the benefit of integrated primary
health care programmes for early detection and treatment of people with risk factors compared to
people in high-income countries.
•People in low- and middle-income countries who suffer from CVDs and other noncommunicable
diseases have less access to effective and equitable health care services which respond to their
needs. As a result, many people in low- and middle-income countries are detected late in the course of
the disease and die younger from CVDs and other noncommunicable diseases, often in their most
productive years.
•The poorest people in low- and middle-income countries are affected most. At the household level,
sufficient evidence is emerging to prove that CVDs and other noncommunicable diseases contribute to
poverty due to catastrophic health spending and high out-of-pocket expenditure.
•At macro-economic level, CVDs place a heavy burden on the economies of low- and middle-income
countries.
10. Pathophysiology
• Atherosclerosis is the major cause of cardiovascular disease. Hypercholesterolaemia,
hypertension and cigarette smoking are the common risk factors for atherosclerosis. These
risk factors unite behind a convergence of mechanism, involving oxidation and inflammation in
the artery wall that, with time, gives rise to characteristic fatty-fibrous lesions. Physical trauma
and inflammation produce lesion rupture, which can lead to clinical events such as heart attack
and stroke, or resolve with plaque growth. Disease progression is marked by the inflammatory
indicator CRP (C-reactive protein). Early indicators of heart attack are the inflammatory marker
CD40, and the cardiac myofilament protein troponin. Coronary atherosclerosis is the common
cause of heart failure (HF). Disordered calcium signalling to the myofilaments occurs in HF and
in cardiomyopathy. Enhanced calcium signalling suppresses HF. Neuro-humoral and
biomechanical processes, as seen in hypertension, produce cardiac hypertrophy, which
predisposes to HF through apoptosis. Although in humans cardiac damage produces
permanent loss of cells, because the heart cannot regenerate, developments in stem cell
technology suggest that help is at hand.